Antimicrobial resistance represents one of the most formidable global health crises of the 21st century, driven by the diminishing efficacy of conventional antibiotics due to bacterial adaptation and biofilm formation. In response, antimicrobial nanoformulations have emerged as a transformative therapeutic paradigm, offering multifaceted and innovative mechanisms to combat resistant pathogens. This comprehensive review delineates the broad scope and distinct novelty of nano-enabled antimicrobial strategies, moving beyond the single-target limitations of traditional drugs. We systematically explore the diverse architectural classes of nanoformulations—including metallic, polymeric, and self-assembling nanostructures—and elucidate their unique mechanistic actions. These encompass (1) physical disruption of microbial membranes via electrostatic interactions; (2) catalytic generation of reactive oxygen and nitrogen species to induce an ‘oxidative storm’; (3) intracellular sabotage of essential metabolic pathways; (4) the ‘Trojan horse’ strategy for enhanced drug delivery and bioavailability; (5) efflux pump bypass to counteract a major resistance mechanism; (6) penetration and eradication of resilient biofilms; and (7) disarming pathogens through quorum sensing and virulence inhibition. Furthermore, this review highlights the immunomodulatory potential of nanoformulations; their activity beyond bacteria against fungi, viruses, and parasites; and the critical role of the nano-bio interface defined by surface physicochemistry. We also address the translational pathway, considering challenges in nanotoxicology, scalability, and regulatory approval, alongside the ecological impact and economic horizon of these technologies. This sector is projected to reach USD 5.4 to 8.96 billion by 2033 to 2034, with compound annual growth rates of 11 to 21% across antimicrobial nanomaterials, nanocoatings, and nanomedicine applications. By integrating insights from computational modeling and in silico design, this review underscores how nanoformulations leverage synergistic, multi-target approaches to overcome resistance, enhance therapeutic efficacy, and represent a significant leap forward in the future of infectious disease management. The novelty lies in the holistic and mechanistic synthesis of how nanotechnology is redefining antimicrobial warfare, offering a promising arsenal to avert a post-antibiotic era.
Gudepu et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: